Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio: prognostic tool for lung cancer
Keywords:
neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, inflammation, prognosis, non-small cell lung cancerAbstract
Lung cancer is the malignant neoplasm that causes higher mortality in the world. Among the prognostic factors of this entity are the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio, hematological parameters that are used to assess inflammation and the immune response in the human body. A bibliographic review was carried out with the objective of exposing the value of the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as a prognostic tool for lung cancer, taking into account the scientific evidence published to date. A total of 46 articles were studied, of which 28 were selected for the development of the research. The quality of the studies, the level of updating on the subject in question, as well as the reliability of the source was used as selection criteria. The resources available in the Infomed network were used to select the information, including PubMed, SciELO and EBSCO, Cumed, LILACS and Scopus, as well as Medline, Academic Search Premier and Medic Latina databases. The value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as a prognostic tool in non-small cell lung cancer at all stages and with different therapeutic modalities was exposed.
Downloads
Download data is not yet available.
References
1. Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1-24. DOI: 10.1016/j.ccm.2019.10.001.
2. Instituto Nacional del Cáncer. Diccionario de cáncer del NCI. Factor pronóstico [Internet]. Maryland: Instituto Nacional del Cáncer; 2016 [citado 19/08/2022]. Disponible en: https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/factor-pronostico
3. Barrón Barrón F, Guzmán de Alba E, Alatorre Alexander J, et al. Guía de Práctica Clínica Nacional para el tratamiento del cáncer de pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos. Salud Publica Mex. 2019;61(3):359-414. DOI: 10.21149/9916.
4. Cervera Deval J, Barrios Benito M, Peñalver Cuesta JC, et al. Cribado de cáncer de pulmón: Supervivencia en un amplio programa de detección precoz en España (I-ELCAP). Arch Bronconeumol [Internet]. 2022 [citado 10/01/2023];58(5):406-11. Disponible en: https://www.archbronconeumol.org/en-cribado-cancer-pulmon-supervivencia-un-articulo-S0300289621003483
5. Vinageras Nenínger E, López Portugal S, Cáceres Lavernia HH, et al. Influencia de enfermedades asociadas en pacientes con cáncer pulmonar no células pequeñas. Rev Cubana Oncol [Internet]. 2020 [citado 19/08/2022];18(3). Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/56
6. Yang R, Chang Q, Meng X, et al. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer. 2018;9(18):3295-302. DOI: 10.7150/jca.25691.
7. Howard R, Kanetsky PA, Egan KM, et al. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019;9:19673. DOI: 10.1038/s41598-019-56218-z.
8. Donate-Moreno MJ, Lorenzo-Sánchez MV, Díaz de Mera-Sánchez Migallón I, et al. Marcadores inflamatorios como factor pronóstico en el cáncer de próstata resistente a la castración metastásico. Actas Urol Esp [Internet]. 2020 [citado 19/08/2022];44(10):692-700. Disponible en: https://medes.com/publication/157024
9. Padmavathi R, Chandrasekaran D, Sundaram S, et al. Preoperative neutrophil–lymphocyte ratio/platelet–lymphocyte ratio: A potential and economical marker for renal cell carcinoma. J Cancer Res Ther. 2022;18(6):1635-9. DOI: 10.4103/jcrt.JCRT_482_20.
10. Assad D, Mascarenhas E, Normando AG, et al. Correlation between salivary and serum CA15-3 concentrations in patients with breast cancer. Mol Clin Oncol. 2020;13(2):155-61. DOI: 10.3892/mco.2020.2062.
11. Fang T, Wang Y, Yin X, et al. Diagnostic Sensitivity of NLR and PLR in Early Diagnosis of Gastric Cancer. J Immunol Res. 2020;e9146042. DOI: 10.1155/2020/9146042.
12. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0.
13. Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol [Internet]. 2020 [citado 19/08/2022];119:199-245. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31997769/
14. Guo W, Cai S, Zhang F, et al. Systemic immuneinflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac Cancer. 2019;10(4):761-8. DOI: 10.1111/1759-7714.12995.
15. Vendramini-Costa DB, Carvalho JR. Molecular Link Mechanisms between Inflamation and Cancer. Curr Pharm Des. 2012;18(26):3831-52. DOI: 10.2174/138161212802083707.
16. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125. DOI: 10.1186/s13045-018-0669-2.
17. Wang W, Tong Y, Sun S, et al. Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer. Front Oncol. 2022;12:936206. DOI: 10.3389/fonc.2022.936206.
18. Wu D, Zhang P, Ma J, et al. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019;8(4):1576-83. DOI: 10.1002/cam4.2055.
19. Sun QY, Zhou HH, Mao XY. Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death. Oxid Med Cell Longev. 2019;e2749173. DOI: 10.1155/2019/2749173.
20. Liang W, Li Q, Ferrara N. Metastatic growth instructed by neutrophil-derived transferrin. Proc Natl Acad Sci. 2018;115(43):11060-5. DOI: 10.1073/pnas.1811717115.
21. Certo M, Tsai C-H, Pucino V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151-61. DOI: 10.1038/s41577-020-0406-2.
22. Cortellini A, Ricciuti B, Borghaei H, et al. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022;128(16):3067-79. DOI: 10.1002/cncr.34348.
23. Rebuzzi SE, Prelaj A, Friedlaender A, et al. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit Rev Oncol Hematol. 2022;179:103806. DOI: 10.1016/j.critrevonc.2022.103806.
24. Hwang M, Canzoniero JV, Rosner S, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022;10(6):e004688. DOI: 10.1136/jitc-2022-004688.
25. Wang J, Li H, Xu R, et al. The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery. BMC Pulm Med. 2022;22(1):104. DOI: 10.1186/s12890-022-01901-7.
26. Li C, Wu J, Jiang L, et al. Correction to: The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. Cancer Immunol Immunother. 2023;72(3):783-94. DOI: 10.1007/s00262-022-03294-2.
27. Delikgoz Soykut E, Kemal Y, Karacin C, et al. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy. J Med Imaging Radiat Oncol. 2022;66(1):146-57. DOI: 10.1111/1754-9485.13341.
28. Lorenzo-Luaces P, Sánchez L, Saavedra D, et al. Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients. BMC Cancer. 2020;20:772. DOI: 10.1186/s12885-020-07284-4.
2. Instituto Nacional del Cáncer. Diccionario de cáncer del NCI. Factor pronóstico [Internet]. Maryland: Instituto Nacional del Cáncer; 2016 [citado 19/08/2022]. Disponible en: https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/factor-pronostico
3. Barrón Barrón F, Guzmán de Alba E, Alatorre Alexander J, et al. Guía de Práctica Clínica Nacional para el tratamiento del cáncer de pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos. Salud Publica Mex. 2019;61(3):359-414. DOI: 10.21149/9916.
4. Cervera Deval J, Barrios Benito M, Peñalver Cuesta JC, et al. Cribado de cáncer de pulmón: Supervivencia en un amplio programa de detección precoz en España (I-ELCAP). Arch Bronconeumol [Internet]. 2022 [citado 10/01/2023];58(5):406-11. Disponible en: https://www.archbronconeumol.org/en-cribado-cancer-pulmon-supervivencia-un-articulo-S0300289621003483
5. Vinageras Nenínger E, López Portugal S, Cáceres Lavernia HH, et al. Influencia de enfermedades asociadas en pacientes con cáncer pulmonar no células pequeñas. Rev Cubana Oncol [Internet]. 2020 [citado 19/08/2022];18(3). Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/56
6. Yang R, Chang Q, Meng X, et al. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. J Cancer. 2018;9(18):3295-302. DOI: 10.7150/jca.25691.
7. Howard R, Kanetsky PA, Egan KM, et al. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019;9:19673. DOI: 10.1038/s41598-019-56218-z.
8. Donate-Moreno MJ, Lorenzo-Sánchez MV, Díaz de Mera-Sánchez Migallón I, et al. Marcadores inflamatorios como factor pronóstico en el cáncer de próstata resistente a la castración metastásico. Actas Urol Esp [Internet]. 2020 [citado 19/08/2022];44(10):692-700. Disponible en: https://medes.com/publication/157024
9. Padmavathi R, Chandrasekaran D, Sundaram S, et al. Preoperative neutrophil–lymphocyte ratio/platelet–lymphocyte ratio: A potential and economical marker for renal cell carcinoma. J Cancer Res Ther. 2022;18(6):1635-9. DOI: 10.4103/jcrt.JCRT_482_20.
10. Assad D, Mascarenhas E, Normando AG, et al. Correlation between salivary and serum CA15-3 concentrations in patients with breast cancer. Mol Clin Oncol. 2020;13(2):155-61. DOI: 10.3892/mco.2020.2062.
11. Fang T, Wang Y, Yin X, et al. Diagnostic Sensitivity of NLR and PLR in Early Diagnosis of Gastric Cancer. J Immunol Res. 2020;e9146042. DOI: 10.1155/2020/9146042.
12. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0.
13. Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol [Internet]. 2020 [citado 19/08/2022];119:199-245. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31997769/
14. Guo W, Cai S, Zhang F, et al. Systemic immuneinflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac Cancer. 2019;10(4):761-8. DOI: 10.1111/1759-7714.12995.
15. Vendramini-Costa DB, Carvalho JR. Molecular Link Mechanisms between Inflamation and Cancer. Curr Pharm Des. 2012;18(26):3831-52. DOI: 10.2174/138161212802083707.
16. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125. DOI: 10.1186/s13045-018-0669-2.
17. Wang W, Tong Y, Sun S, et al. Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer. Front Oncol. 2022;12:936206. DOI: 10.3389/fonc.2022.936206.
18. Wu D, Zhang P, Ma J, et al. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Med. 2019;8(4):1576-83. DOI: 10.1002/cam4.2055.
19. Sun QY, Zhou HH, Mao XY. Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death. Oxid Med Cell Longev. 2019;e2749173. DOI: 10.1155/2019/2749173.
20. Liang W, Li Q, Ferrara N. Metastatic growth instructed by neutrophil-derived transferrin. Proc Natl Acad Sci. 2018;115(43):11060-5. DOI: 10.1073/pnas.1811717115.
21. Certo M, Tsai C-H, Pucino V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151-61. DOI: 10.1038/s41577-020-0406-2.
22. Cortellini A, Ricciuti B, Borghaei H, et al. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022;128(16):3067-79. DOI: 10.1002/cncr.34348.
23. Rebuzzi SE, Prelaj A, Friedlaender A, et al. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit Rev Oncol Hematol. 2022;179:103806. DOI: 10.1016/j.critrevonc.2022.103806.
24. Hwang M, Canzoniero JV, Rosner S, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022;10(6):e004688. DOI: 10.1136/jitc-2022-004688.
25. Wang J, Li H, Xu R, et al. The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery. BMC Pulm Med. 2022;22(1):104. DOI: 10.1186/s12890-022-01901-7.
26. Li C, Wu J, Jiang L, et al. Correction to: The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. Cancer Immunol Immunother. 2023;72(3):783-94. DOI: 10.1007/s00262-022-03294-2.
27. Delikgoz Soykut E, Kemal Y, Karacin C, et al. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy. J Med Imaging Radiat Oncol. 2022;66(1):146-57. DOI: 10.1111/1754-9485.13341.
28. Lorenzo-Luaces P, Sánchez L, Saavedra D, et al. Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients. BMC Cancer. 2020;20:772. DOI: 10.1186/s12885-020-07284-4.
Downloads
Published
2023-12-16
How to Cite
1.
Camacho-Sosa K, Ramos-Suzarte M, Viada-González CE. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio: prognostic tool for lung cancer. Rev Méd Electrón [Internet]. 2023 Dec. 16 [cited 2025 Jan. 10];45(6):e5329. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/5329
Issue
Section
Review article
License
All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.
It allows:
- Copy and redistribute published material in any medium or format.
- Adapt the content.
This will be done under the following terms:
- Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.
- Non-commercial use.
- Recognize the journal where it is published.
The copyrights of each article are maintained, without restrictions.
Guidelines to authors
